Laboratory biosafety measures of SARS-CoV-2 at containment level 2 with particular reference to its more infective variants  

作　　者：Wafa Naeem Habiba Zeb Muhammad Ibrahim Rashid 

机构地区：[1]Department of Molecular Biology&Genetics,Institute of Basic Medical Sciences,Khyber Medical University,Peshawar 25000,Pakistan

出　　处：《Biosafety and Health》2022年第1期11-14,共4页生物安全与健康（英文）

摘　　要：The novel betacoronavirus(Severe Acute Respiratory Syndrome Coronavirus 2,SARS‐CoV‐2)is a pathogen that causes deadly respiratory disease named coronavirus disease 2019(COVID‐19).The incidence of this disease has increased in the last few months affecting 257,832,881 people in 221 countries and 51,68,069 deaths worldwide according to Worldometer at 04:03 GMT on November 22,2021.Thus,the emergence of this disease creates a challenge for health care providers in handling this pathogen and reducing its risk of transmission.In developing countries,this virus is treated in biosafety level 2 laboratories,where a high concentration of pathogen can easily affect the laboratory staff and cause the spread of this disease.Based on the epidemiology and characteristics of the SARS‐CoV‐2 virus already discussed in recent studies,we will provide biosafety guidelines and suggestions for safe handling and transportation of the SARS‐CoV‐2 virus in dealing with the current pandemic situation with a focus on increased infectivity of emerging new variants.

关 键 词：SARS‐CoV‐2 Biosafety guidelines COVID‐19 PPE Laboratory acquired infections 

分 类 号：R563.1[医药卫生—呼吸系统]